Why I’m buying more of the British American Tobacco share price after falling 50% in a year

Rupert Hargreaves explains why he believes British American Tobacco plc (LON: BATS) continues to deserve a place in his portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in FTSE 100 dividend stalwart British American Tobacco (LSE: BATS) have cratered over the past 12 months. Excluding dividends, since November 2017, the stock has lost nearly 50% of its value. 

Including distributions to investors, British American has produced a return of -42%, underperforming the FTSE 100 by 40%.

Today, I’m going to look at the reasons behind this decline and explain why I think now is the time to be greedy while other investors are fearful.

The perfect storm

Until 2018, British American was considered to be one of the most defensive and reliable income investments in the FTSE 100. But this year, the company has been hit by what I can only call a perfect storm of events.

The company spent 2017 showing off its new range of so-called reduced risk products to investors. These devices, such as e-cigarettes and heat-not-burn cigarette products would, according to management, generate billions of dollars of additional sales and guarantee the firm’s future for many years to come.

This story started to unravel in 2018 when one of the company’s competitors announced worse than expected sales growth of reduced risk products in Japan, a key market. Following this development, investors, and analysts have begun to question whether these devices will be the golden goose tobacco companies seem to believe they are.

The next hammer blow to the firm came a few weeks ago when the US Food and Drug Administration (FDA) announced that it is planning to bring in a ban on menthol cigarettes

Sales of menthol cigarettes in the US account for around 25% of British Amercian’s bottom line. Losing this considerable market will not only mean a drop in profits but also could force management to cut the highly coveted dividend.

Not the end of the world

Cigarette sales have been sliding for decades, and we have known that, sooner or later, tobacco companies will have to face the music. Developments this year seem to have shocked investors into thinking that the end might be closer than they initially believed.

However, I think the selling is overdone. Before it can bring in a full ban on menthol cigarettes, the FDA has to prove that they are substantially worse than the non-menthol versions. Big Tobacco plans to fight this in the courts, which could take many years to move through the US legal system. And even if a ban does come into place, the addictive nature of tobacco means smokers are unlikely to quit overnight. It is more than likely that they will switch to the non-menthol variant first.

At the same time, reduced risk product sales are still expanding, they’re just not expanding as fast as analysts have been predicting.

Dividend support 

Considering the above, I think British American will remain a FTSE 100 income champion for many years to come. The payout is well covered by earnings per share (1.5x) and analysts are expecting earnings to increase by 20% over the next two years. There’s no denying that cigarette sales are in terminal decline, but this has been the case for several decades now, and British American has always come out on top. Right now the shares yield 7.2%  and trade at a forward P/E of only 8.7, which I believe offers fair compensation for the risks of investing in the sector. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares in British American Tobacco. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »